SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

COGT

Cogent Biosciences, Inc.
NASDAQHealth Care

Latest close: 29.52 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 2, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 27, 2026Reported sale · Form 4Arlene Morris · $1.6MOpen the filing ↗
  3. Aug 27, 2026Reported sale · Form 4Arlene Morris · $118.7KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record56922 flagged findings
Reported transactions (Form 4)77since Jun 9, 2023 · and 1 other holding
Corporate events (8-K)30since Jul 6, 2020

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-05share offering or dilution eventrecentOpen filing ↗
    “…and their ability to perform adequately; • the development and success of competing therapies that are or may be under…”
    +1 more passage from the same document
    • “…Property and equipment, net 5,298 5,457 Restricted cash 416 416 Other assets 1,940 3,301 Total assets $ 903,006 $ 937,607…”
  • 2026-02-17share offering or dilution eventrecentOpen filing ↗
    “…• The price of our stock may be volatile, and you could lose all or part of your investment. • Our indebtedness and…”
    +1 more passage from the same document
    • “…and their ability to perform adequately; • the development and success of competing therapies that are or may be under…”
  • 2026-02-17capital return (buybacks/dividends)recentOpen filing ↗
    “…of our company less attractive or more difficult. Any of these factors could harm our business, prospects, operating results…”
    +1 more passage from the same document
    • “…the risks related to our business and our ability to service or repay our indebtedness would increase. We may be unable to…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 569)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 5, 26Form 4 ↗Insider transaction
  • Sep 2, 268-K ↗Current report · Entered a material agreement
  • Aug 31, 26Form 4 ↗Insider transaction
  • Aug 27, 26Form 144 ↗Notice of proposed sale
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · Deerfield Mgmt, L.P. · 2.9% · event on Jun 30, 26 · amendment
  • Aug 10, 268-K ↗Current report · Other events
  • Aug 10, 26424B5 ↗Securities offering
  • Aug 10, 2610-Q ↗Quarterly report
  • Aug 10, 268-K ↗Current report · Results
  • Jul 31, 26SCHEDULE 13G ↗Passive stake · Vanguard Capital Management · 5.1% · event on Jun 30, 26
  • Jul 27, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 8.0% · event on Jun 30, 26 · amendment
  • Insider transaction · 7 Form 4 filingsshow all 7hide
  • Jun 11, 268-K ↗Current report · Shareholder vote results
  • May 21, 26Form 4 ↗Insider transaction
  • May 14, 26SCHEDULE 13G/A ↗Passive stake · Deerfield Mgmt, L.P. · 5.3% · event on Mar 31, 26 · amendment
  • May 5, 2610-Q ↗Quarterly report
  • May 5, 268-K ↗Current report · Results
  • Apr 23, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 23, 26DEF 14A ↗Shareholder meeting and votes

569 filings on record, the oldest from Dec 4, 17.

Listing the 25 most recent filings of the 569 on record.

8-Ks, explained

Stress2Structure29Governance12
  • Structure6 material agreements entered2025 – 2026show all 6hide
    • Sep 2, 26StructureEntered a material agreement8-K 1.01 ↗
    • Nov 18, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Nov 13, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Sep 11, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Jul 10, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Jun 11, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Mar 22, 24StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗
  • Feb 14, 24StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Jun 8, 23StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jun 7, 23GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 16, 22StructureEntered a material agreement+2 more in the same filing8-K/A 1.01 ↗
  • Jun 15, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • May 6, 22StructureA material agreement was terminated8-K 1.02 ↗
  • Dec 27, 21GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jul 9, 21StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jun 17, 21GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 22, 21GovernanceA senior executive left or was appointed8-K 5.02 ↗

6 older filings not shown · The record reaches back to Jan 3, 19.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Mar 2, 20StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Jan 6, 20StressListing notice (8-K 3.01)8-K 3.01 ↗

The full record holds 2 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Fairmount Funds Management LLC8.6%Mar 31, 26SCHEDULE 13D/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • BlackRock, Inc.8.0%Jun 30, 26SCHEDULE 13G/A ↗2 earlier filings
  • The Vanguard Group7.5%Dec 31, 25SCHEDULE 13G/A ↗
  • Vanguard Capital Management5.1%Jun 30, 26SCHEDULE 13G ↗
  • TCG Crossover GP I, LLC4.8%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Kynam Capital Management, LP4.3%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
show 4 more holdershide
  • Point72 Asset Management, L.P.4.0%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Deerfield Mgmt, L.P.2.9%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Paradigm BioCapital Advisors LP2.3%Sep 30, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Commodore Capital LP1.8%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Aug 27, ARLENE MORRIS filed notice of intent to sell up to $1.7M. That is about 0.03% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $1.7M across 2 trades on Aug 27, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Aug 27, 26Sell$1.6MArlene Morris↗
  • Aug 27, 26Sell$119KArlene Morris↗
  • Mar 31, 26Sell$242.6MFairmount Funds Management LLC↗
  • Jan 22, 26Sell$127.4MFairmount Funds Management LLC↗
  • Dec 26, 25Sell$3.5MJohn Edward RobinsonChief Scientific Officer↗
  • Dec 26, 25Sell$3.2MJessica SachsChief Medical Officer↗
  • Dec 26, 25Sell$3.0MJohn L. GreenChief Financial Officer↗
  • Dec 26, 25Sell$2.5MEvan KearnsChief Legal Officer↗
  • Jul 10, 25Buy$25.0MFairmount Funds Management LLC↗
  • Jan 14, 25Buy$332KCole PinnowChief Commercial Officer↗
  • Jun 9, 23Buy$9.6MFairmount Funds Management LLC↗
Stock compensation, tax and giftsshow the 26 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 27, 26Compensation$236KArlene Morris↗
  • Aug 27, 26Compensation$9KArlene Morris↗
  • May 19, 26Giftamount n/aAndrew R RobbinsPresident and CEO↗
  • Mar 31, 26Otheramount n/aFairmount Funds Management LLC↗
  • Dec 17, 25Compensationamount n/aJohn L. GreenChief Financial Officer↗
  • Dec 17, 25Compensationamount n/aJohn L. GreenChief Financial Officer↗
  • Dec 17, 25Tax$5.7MJohn L. GreenChief Financial Officer↗
  • Dec 17, 25Compensationamount n/aEvan KearnsChief Legal Officer↗
  • Dec 17, 25Compensationamount n/aEvan KearnsChief Legal Officer↗
  • Dec 17, 25Tax$5.0MEvan KearnsChief Legal Officer↗
  • Dec 17, 25Compensationamount n/aJessica SachsChief Medical Officer↗
  • Dec 17, 25Compensationamount n/aJessica SachsChief Medical Officer↗
  • Dec 17, 25Tax$6.1MJessica SachsChief Medical Officer↗
  • Dec 17, 25Compensationamount n/aCole PinnowChief Commercial Officer↗
  • Dec 17, 25Compensationamount n/aCole PinnowChief Commercial Officer↗
  • Dec 17, 25Tax$3.7MCole PinnowChief Commercial Officer↗
  • Dec 17, 25Compensationamount n/aAndrew R RobbinsPresident and CEO↗
  • Dec 17, 25Compensationamount n/aAndrew R RobbinsPresident and CEO↗
  • Dec 17, 25Tax$14.5MAndrew R RobbinsPresident and CEO↗
  • Dec 17, 25Compensationamount n/aJohn Edward RobinsonChief Scientific Officer↗
  • Dec 17, 25Compensationamount n/aJohn Edward RobinsonChief Scientific Officer↗
  • Dec 17, 25Tax$5.5MJohn Edward RobinsonChief Scientific Officer↗
  • Jun 10, 24Compensationamount n/aFairmount Funds Management LLC↗
  • Mar 28, 24Otheramount n/aFairmount Funds Management LLC↗
  • Mar 28, 24Otheramount n/aFairmount Funds Management LLC↗
  • Feb 16, 24Compensation$8.7MFairmount Funds Management LLC↗

The full record holds 37 transactions and goes back to Jan 3, 23.

Its sector and its market

Cogent Biosciences, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Cogent Biosciences, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Cogent Biosciences, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
569 documents on file, from Dec 4, 2017 to Oct 5, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.